Advertisement

The outcome of initial mitomycin C-augmented trabeculectomy with subconjunctival bevacizumab in the management of secondary glaucoma associated with Fuchs heterochromic iridocyclitis

  • Ufuk ElginEmail author
  • Emine Sen
  • Kubra Ozdemir
  • Pinar Ozdal
  • Nilufer Berker
Original Paper
  • 27 Downloads

Abstract

Purpose

To investigate the outcome of mitomycin C (MMC)-augmented trabeculectomy with subconjunctival bevacizumab in the management of Fuchs heterochromic iridocyclitis (FHI)-related glaucoma in 1-year follow-up period.

Methods

This retrospective study included 50 eyes with FHI-related glaucoma those had underwent initial trabeculectomy with MMC (0.2 mg/ml—3 min). Thirty-one of them had single-dose bevacizumab injection (1.25 mg/0.05 ml) into the bleb area just at the end of the surgery, while 19 eyes did not have. The intraocular pressure (IOP) and the mean number of anti-glaucomatous medications were evaluated. The IOP value ≤ 21 mmHg was defined as complete or qualified surgical success in terms of using medical anti-glaucomatous treatment. Bleb height and vascularity were evaluated with Indiana bleb grading system. Paired sample t test, t test, Chi-square and Kolmogorov–Smirnov tests were used for statistical analysis.

Results

The preoperative IOP values of bevacizumab and without bevacizumab groups were 32.8 ± 4.5 mmHg and 32.8 ± 4.5 mmHg, respectively, and they decreased to 17.5 ± 4.6 mmHg and 17 ± 5.2 mmHg at the final visit (p < 0.001 for all values). There were no significant differences in postoperative IOP and the number of medications between the groups at the final visit. In bevacizumab group, complete success was achieved in 100% within the third month but decreased to 22.5% (complete) and 74.1% (qualified) at the first year. In the other group (without bevacizumab group), complete success was achieved in 94.7% within the third month but decreased to 15.8% (complete) and 84.2% (qualified) at the first year.

Conclusion

Initial trabeculectomy with MMC and subconjunctival bevacizumab injection was found to have lower rates of complete success with relatively acceptable qualified success rates in the management of FHI-related glaucoma. Subconjunctival bevacizumab was not found to have additional effect to improve the surgical success.

Keywords

Fuchs heterochromic iridocyclitis Glaucoma Trabeculectomy Mitomycin C Subconjunctival Bevacizumab 

Notes

Funding

None of the authors received any financial support or funds and have no financial interests.

Compliance with ethical standards

Ethical approval

Our presentation was approved by Ethics Committee of Numune Training and Research Hospital.

Informed consent

Written informed consent was taken from the participants.

References

  1. 1.
    Siddique SS, Suelves AM, Baheti U, Foster CS (2013) Glaucoma and uveitis. Surv Ophthalmol 58:1–10CrossRefGoogle Scholar
  2. 2.
    Al Rubaie K, Al Dhahri H, Al Fawaz A et al (2016) Incidence and risk factors for developing glaucoma among patients with uveitis in a university-based tertiary referral center in Riyadh, Saudi Arabia. Ocul Immunol Inflamm 24:571–578CrossRefGoogle Scholar
  3. 3.
    Tugal-Tutkun I, Güney-Tefekli E, Kamaci-Duman F, Corum I (2009) A cross-sectional and longitudinal study of Fuchs uveitis syndrome in Turkish patients. Am J Ophthalmol 148:510–515CrossRefGoogle Scholar
  4. 4.
    Nalçacıoğlu P, Çakar Özdal P, Şimşek M (2016) Clinical characteristics of Fuchs’ uveitis syndrome. Turk J Ophthalmol 46:52–57CrossRefGoogle Scholar
  5. 5.
    Norrsell K, Sjödell L (2008) Fuchs’ heterochromic uveitis: a longitudinal clinical study. Acta Ophthalmol 86:58–64CrossRefGoogle Scholar
  6. 6.
    Toniolo JT, Hall AJ, Smith JG, Levy J, Lim LL (2017) Risk factors for glaucoma in a cohort of patients with Fuchs heterochromic iridocyclitis. Ocul Immunol Inflamm 25(6):753–759CrossRefGoogle Scholar
  7. 7.
    Hwang DK, Chou YJ, Pu CY, Chou P (2015) Risk factors for developing glaucoma among patients with uveitis: a nation wide study in Taiwan. J Glaucoma 24:219–224CrossRefGoogle Scholar
  8. 8.
    Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser-Bell S (2018) Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database Syst Rev 18(4):CD011599.  https://doi.org/10.1002/14651858.cd011599.pub2 CrossRefGoogle Scholar
  9. 9.
    Ashraf M, Banaee T, Silva FQ, Singh RP (2018) Switching anti-vascular endothelial growth factors in refractory neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina 49:166–170CrossRefGoogle Scholar
  10. 10.
    Kaushik J, Parihar JK, Jain VK et al (2017) Efficacy of bevacizumab compared to mitomycin C modulated trabeculectomy in primary open angle glaucoma: a one-year prospective randomized controlled study. Curr Eye Res 42:217–224CrossRefGoogle Scholar
  11. 11.
    Vahedian Z, Mafi M, Fakhraie G et al (2017) Short- term results of trabeculectomy using adjunctive intracameral bevacizumab versus mitomycin C: a randomized controlled trial. J Glaucoma 26:829–834PubMedGoogle Scholar
  12. 12.
    Elgin U, Sen E, Çolak S, Yilmazbas P (2019) Initial trabeculectomy with 5-fluorouracil with or without subconjunctival bevacizumab in the management of pseudoexfoliation glaucoma. Int Ophthalmol 39(6):1211–1217CrossRefGoogle Scholar
  13. 13.
    De Fendi LI, Arruda GV, Scott IU, Paula JS (2013) Mitomycin C versus 5-fluorouracil as an adjunctive treatment for trabeculectomy: a meta-analysis of randomized clinical trials. Clin Exp Ophthalmol 41:798–806CrossRefGoogle Scholar
  14. 14.
    Chawla A, Mercieca K, Fenerty C, Jones NP (2013) Outcomes and complications of trabeculectomy enhanced with 5-fluorouracil in adults with glaucoma secondary to uveitis. J Glaucoma 22:663–666CrossRefGoogle Scholar
  15. 15.
    Almobarak FA, Alharbi AH, Morales J, Aljadaan I (2018) The influence of mitomycin C concentration on the outcome of trabeculectomy in uveitic glaucoma. Int Ophthalmol 38(6):2371–2379CrossRefGoogle Scholar
  16. 16.
    Almobarak FA, Alharbi AH, Morales J, Aljadaan I (2016) Outcomes of trabeculectomy with mitomycin-C in uveitis associated with Vogt–Koyanagi–Harada Disease. J Glaucoma 25:528–532CrossRefGoogle Scholar
  17. 17.
    Komae K, Takamoto M, Tanaka R et al (2017) Initial trabeculectomy with mitomycin-C for secondary glaucoma-associated with Uveitis in Behçet disease patients. J Glaucoma 26:603–607CrossRefGoogle Scholar
  18. 18.
    You YA, Wu Y, Hu S (2013) Surgical management of secondary glaucoma in Fuchs’ heterochromic iridocyclitis. Graefes Arch Clin Exp Ophthalmol 251:1785–1790CrossRefGoogle Scholar
  19. 19.
    Ozgonul C, Mumcuoglu T, Gunal A (2014) The effect of bevacizumab on wound healing modulation in an experimental trabeculectomy model. Curr Eye Res 39:451–459CrossRefGoogle Scholar
  20. 20.
    Tai TY, Moster MR, Pro MJ, Myers JS, Katz LJ (2015) Needle bleb revision with bevacizumab and mitomycin C compared with mitomycin C alone for failing filtration blebs. J Glaucoma 24:311–315CrossRefGoogle Scholar
  21. 21.
    Simsek T, Cankaya AB, Elgin U (2012) Comparison of needle revision with subconjunctival bevacizumab and 5- fluorouracil injection of failed trabeculectomy blebs. J Ocul Pharmacol Ther 28:542–546CrossRefGoogle Scholar
  22. 22.
    Bettis DI, Morshedi RG, Chaya C, Goldsmith J, Crandall A, Zabriskie N (2015) Trabeculectomy with mitomycin C or Ahmed valve implantation in eyes with uveitic glaucoma. J Glaucoma 24:591–599CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Ulucanlar Eye Education and Research HospitalUniversity of Health SciencesAltindagTurkey

Personalised recommendations